Related Experiment Video

Updated: Apr 20, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K

Withaferin A Inhibits STAT3 and Induces Tumor Cell Death in Neuroblastoma and Multiple Myeloma

Lisette P Yco1, Gabor Mocz2, John Opoku-Ansah3

  • 1Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, USA. ; Department of Molecular Biosciences and Bioengineering, University of Hawaii at Manoa, Honolulu, Hawaii, USA.

Biochemistry Insights
|December 3, 2014
PubMed

Insights

Withaferin A (WFA) effectively kills neuroblastoma and multiple myeloma cells by inhibiting signal transducer and activator of transcription 3 (STAT3). WFA targets STAT3 phosphorylation and transcriptional activity, suggesting its potential as an anticancer therapeutic.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is a key oncogenic transcription factor targeted in cancer therapy.
  • Withaferin A (WFA), a natural product, exhibits antiproliferative properties and interacts with molecular targets including STAT3.
  • The effects of WFA on pediatric neuroblastoma (NB) and its STAT3 interaction remain underexplored.

Purpose of the Study:

  • To investigate the efficacy of WFA in pediatric neuroblastoma (NB) and multiple myeloma (MM) tumor cells.
  • To elucidate the mechanism of WFA's action, specifically its interaction with STAT3.
  • To assess WFA's potential as a therapeutic agent for NB and MM.

Main Methods:

  • Treatment of NB and MM cells with WFA.
  • Assessment of STAT3 phosphorylation at Y705 and transcriptional activity.
  • Computational modeling to predict WFA binding to STAT3.

Main Results:

  • WFA induced dose-dependent cell death in high-risk, drug-resistant NB and MM cells.
  • WFA inhibited interleukin-6 (IL-6)-mediated STAT3 phosphorylation at Y705.
  • WFA blocked STAT3 transcriptional activity, with computational models suggesting binding near the Y705 residue in the STAT3 SH2 domain, inhibiting dimer formation.

Conclusions:

  • WFA demonstrates significant antitumor activity in NB and MM models.
  • The anticancer effects of WFA are partly mediated by STAT3 inhibition.
  • WFA represents a promising candidate for further drug development and clinical application in NB and MM.
Keywords:
Withaferin A (WFA)molecular modelingmultiple myelomanatural productspediatric cancer neuroblastomasignal transducer and activator of transcription 3 (STAT3)

More Related Videos

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

1.2K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K